OTCMKTS:NWBO - Northwest Biotherapeutics Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$0.2020 0.00 (0.00 %)
(As of 08/16/2018 04:00 PM ET)
Previous Close$0.20
Today's Range$0.2005 - $0.2050
52-Week Range$0.1550 - $0.3980
Volume683,218 shs
Average Volume803,391 shs
Market Capitalization$94.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Receive NWBO News and Ratings via Email

Sign-up to receive the latest news and ratings for NWBO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:NWBO
CUSIPN/A
Phone240-497-9024

Debt

Debt-to-Equity Ratio-0.08
Current Ratio0.01
Quick Ratio0.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$330,000.00
Price / Sales273.60
Cash FlowN/A
Price / CashN/A
Book Value($0.20) per share
Price / Book-1.01

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-73,140,000.00
Net Margins-19,633.73%
Return on EquityN/A
Return on Assets-129.48%

Miscellaneous

Employees16
Outstanding Shares446,970,000
Market Cap$94.31 million

Northwest Biotherapeutics (OTCMKTS:NWBO) Frequently Asked Questions

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO."

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) posted its earnings results on Monday, August, 10th. The biotechnology company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.22. The biotechnology company had revenue of $0.39 million for the quarter, compared to analysts' expectations of $0.20 million. View Northwest Biotherapeutics' Earnings History.

When is Northwest Biotherapeutics' next earnings date?

Northwest Biotherapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 20th 2018. View Earnings Estimates for Northwest Biotherapeutics.

What price target have analysts set for NWBO?

0 analysts have issued 12-month price targets for Northwest Biotherapeutics' stock. Their forecasts range from $0.23 to $0.23. On average, they anticipate Northwest Biotherapeutics' share price to reach $0.23 in the next year. This suggests a possible upside of 13.9% from the stock's current price. View Analyst Price Targets for Northwest Biotherapeutics.

Who are some of Northwest Biotherapeutics' key competitors?

Who are Northwest Biotherapeutics' key executives?

Northwest Biotherapeutics' management team includes the folowing people:
  • Ms. Linda F. Powers J.D., Chairperson, CEO, Pres & CFO (Age 62)
  • Dr. Alton L. Boynton, Founder, Chief Scientific Officer, Sec. & Director (Age 73)
  • Dr. Marnix L. Bosch Ph.D., MBA, Chief Technical Officer (Age 59)
  • Mr. Leslie J. Goldman, Sr. VP of Bus. Devel. (Age 73)
  • Ms. Susan Goldman, Director of Patient Affairs

Has Northwest Biotherapeutics been receiving favorable news coverage?

Media coverage about NWBO stock has trended somewhat positive on Thursday, Accern reports. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Northwest Biotherapeutics earned a coverage optimism score of 0.02 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Northwest Biotherapeutics.

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Northwest Biotherapeutics' stock price today?

One share of NWBO stock can currently be purchased for approximately $0.2020.

How big of a company is Northwest Biotherapeutics?

Northwest Biotherapeutics has a market capitalization of $94.31 million and generates $330,000.00 in revenue each year. Northwest Biotherapeutics employs 16 workers across the globe.

How can I contact Northwest Biotherapeutics?

Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The biotechnology company can be reached via phone at 240-497-9024 or via email at [email protected]


MarketBeat Community Rating for Northwest Biotherapeutics (OTCMKTS NWBO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  139
MarketBeat's community ratings are surveys of what our community members think about Northwest Biotherapeutics and other stocks. Vote "Outperform" if you believe NWBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.